Study of major cardiovascular events in patients with nonvalvular atrial fibrillation treated with Rivaroxaban (EMIR)
Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain
- Adult patients aged 18 years or older. - Patients with diagnosis of NVAF. - Patients treated with rivaroxaban from at least six months prior to the study inclusion. - Patients who have been given appropriate information about the study objectives and procedures and who have given their written informed consent.
- Patients participating in an investigational program with interventions outside of routine clinical practice. - Patients who initiate treatment with rivaroxaban after the start of the study inclusion period. - Prosthetic heart valves or the presence of any severe valvulopathies. - Patients with severe cognitive impairment. - Patients with chronic infections (HIV infection, hepatitis C virus, hepatitis B virus) or systemic autoimmune diseases. - Patients with active cancer. - Patients with liver insufficiency (eg. cirrhosis).
Many Locations, Spain
E-mail: [email protected]
Phone: (+) 1-888-8422937
Study of risk factors of major cardiovascular events in patients with nonvalvular atrial fibrillation treated with a direct oral anticoagulant (Rivaroxaban)